{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:28:25Z","timestamp":1779233305652,"version":"3.51.4"},"reference-count":30,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Parathyroid carcinoma (PC) is extremely rare and is primarily treated surgically. Chemotherapy is an option for advanced stages, but no standard regimen exists. Emerging research suggests the efficacy of multitarget tyrosine kinase inhibitors (MTKIs) for PC, targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). A 61-year-old Japanese woman presented with a neck mass, diagnosed as PC with pleural and lumbar metastases. After parathyroidectomy and radiation for lumbar metastasis, immunohistochemistry showed VEGFR overexpression, leading to targeted therapy with MTKIs. Despite no actionable mutations on cancer genomic panel test, a novel MEN1 somatic mutation (NM_130801: exon2: c.332delG: p.G111fs*8) was identified, which may affect VEGFR2 expression and tumor epigenetics. Although severe hand-foot syndrome necessitated dose reductions and treatment interruptions, sorafenib treatment managed hypercalcemia with evocalcet and denosumab. Lenvatinib, as second-line therapy, was effective against pleural metastases but caused thrombocytopenia and hematuria, leading to discontinuation and uncontrolled recurrence and metastasis progression. Our case highlights the need for further research on genomic profiling, molecular targets, and therapy response in PC.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae121","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:39:39Z","timestamp":1721875179000},"source":"Crossref","is-referenced-by-count":5,"title":["Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic <i>MEN1<\/i> Mutation"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8785-1294","authenticated-orcid":false,"given":"Yu","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Gifu Prefectural General Medical Center , Gifu 500-8717 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-1893","authenticated-orcid":false,"given":"Toshinori","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism\/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu 501-1194 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-1714","authenticated-orcid":false,"given":"Hisashi","family":"Daido","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Gifu Prefectural General Medical Center , Gifu 500-8717 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-2463","authenticated-orcid":false,"given":"Takehiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism\/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu 501-1194 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-7687","authenticated-orcid":false,"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism\/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine , Gifu 501-1194 , Japan"},{"name":"Center for One Medicine Innovative Translational Research, Gifu University , Gifu 501-1194 , Japan"},{"name":"Departments of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"6","key":"2024081401412593400_luae121-B1","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/cancers14061426","article-title":"Parathyroid carcinoma: incidence, survival analysis, and management: a study from the SEER database and insights into future therapeutic perspectives","volume":"14","author":"Ullah","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024081401412593400_luae121-B2","doi-asserted-by":"crossref","first-page":"997009","DOI":"10.3389\/fonc.2022.997009","article-title":"Treatment and outcome of metastatic parathyroid carcinoma: a systematic review and pooled analysis of published cases","volume":"12","author":"Alberti","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"2024081401412593400_luae121-B3","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.9261-21","article-title":"Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma","volume":"61","author":"Makino","year":"2022","journal-title":"Intern Med"},{"issue":"1","key":"2024081401412593400_luae121-B4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2024081401412593400_luae121-B5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"2024081401412593400_luae121-B6","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1245\/s10434-015-4672-3","article-title":"Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the national cancer data base (NCDB)","volume":"22","author":"Asare","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2024081401412593400_luae121-B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2796.1998.00346.x","article-title":"Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene","volume":"243","author":"Guru","year":"1998","journal-title":"J Intern Med"},{"issue":"3-4","key":"2024081401412593400_luae121-B8","first-page":"105","article-title":"Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis","volume":"79","author":"Busygina","year":"2006","journal-title":"Yale J Biol Med"},{"issue":"5311","key":"2024081401412593400_luae121-B9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"4","key":"2024081401412593400_luae121-B10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ng0897-375","article-title":"Somatic mutation of the MEN1 gene in parathyroid tumours","volume":"16","author":"Heppner","year":"1997","journal-title":"Nat Genet"},{"issue":"1","key":"2024081401412593400_luae121-B11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-015-0041-2","article-title":"Novel MEN 1 gene findings in rare sporadic insulinoma\u2013a case control study","volume":"15","author":"Jyotsna","year":"2015","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2024081401412593400_luae121-B12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11102-023-01336-1","article-title":"Sporadic pituitary adenoma with somatic double-hit loss of MEN1","volume":"26","author":"Hong","year":"2023","journal-title":"Pituitary"},{"issue":"10","key":"2024081401412593400_luae121-B13","doi-asserted-by":"crossref","first-page":"E1995","DOI":"10.1210\/jc.2012-2303","article-title":"Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas","volume":"97","author":"Newey","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024081401412593400_luae121-B14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1634\/theoncologist.2018-0334","article-title":"Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"2024081401412593400_luae121-B15","doi-asserted-by":"crossref","first-page":"e220479","DOI":"10.1530\/EC-22-0479","article-title":"Clinical and molecular characterization of parathyroid carcinoma in multiple endocrine neoplasia type 1","volume":"12","author":"Lomelino Pinheiro","year":"2023","journal-title":"Endocr Connect"},{"issue":"6","key":"2024081401412593400_luae121-B16","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.21873\/anticanres.12646","article-title":"Co-occurrence of MEN1 p.Gly111fs and AIP p.Arg16His variants in familial MEN1 phenotype","volume":"38","author":"DE Melo","year":"2018","journal-title":"Anticancer Res"},{"issue":"6","key":"2024081401412593400_luae121-B17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41422-022-00613-1","article-title":"Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells","volume":"32","author":"Ma","year":"2022","journal-title":"Cell Res"},{"issue":"4","key":"2024081401412593400_luae121-B18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12022-012-9222-y","article-title":"Biomarkers of parathyroid carcinoma","volume":"23","author":"Erovic","year":"2012","journal-title":"Endocr Pathol"},{"key":"2024081401412593400_luae121-B19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12935-018-0530-2","article-title":"Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma","volume":"18","author":"Lai","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"8","key":"2024081401412593400_luae121-B20","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00432-019-02945-9","article-title":"Genetic profiling as a clinical tool in advanced parathyroid carcinoma","volume":"145","author":"Kutahyalioglu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2024081401412593400_luae121-B21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2024081401412593400_luae121-B22","doi-asserted-by":"crossref","first-page":"1153991","DOI":"10.3389\/fphar.2023.1153991","article-title":"Lenvatinib resistance mechanism and potential ways to conquer","volume":"14","author":"Bo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"2024081401412593400_luae121-B23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/cas.12826","article-title":"Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Kiyota","year":"2015","journal-title":"Cancer Sci"},{"issue":"3","key":"2024081401412593400_luae121-B24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ajpath.2016.10.021","article-title":"miR-24 inhibition increases menin expression and decreases cholangiocarcinoma proliferation","volume":"187","author":"Ehrlich","year":"2017","journal-title":"Am J Pathol"},{"issue":"1","key":"2024081401412593400_luae121-B25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-17-0580","article-title":"Pharmacologic inhibition of the menin-MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma","volume":"17","author":"Kempinska","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2024081401412593400_luae121-B26","doi-asserted-by":"crossref","first-page":"e005693","DOI":"10.1136\/jitc-2022-005693","article-title":"H3k4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy","volume":"11","author":"Xiao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2024081401412593400_luae121-B27","doi-asserted-by":"crossref","first-page":"1376916","DOI":"10.3389\/fonc.2024.1376916","article-title":"Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"2024081401412593400_luae121-B28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/thy.2022.0439","article-title":"Hypocalcemia during lenvatinib treatment for advanced thyroid cancer: clinical features and management in a real-life setting","volume":"33","author":"De Leo","year":"2023","journal-title":"Thyroid"},{"issue":"11","key":"2024081401412593400_luae121-B29","first-page":"1213","article-title":"Intratumor heterogeneity in human parathyroid tumors","volume":"35","author":"Verdelli","year":"2020","journal-title":"Histol Histopathol"},{"key":"2024081401412593400_luae121-B30","doi-asserted-by":"crossref","first-page":"543562","DOI":"10.3389\/fonc.2020.543562","article-title":"VEGFR2 promotes metastasis and PD-L2 expression of human osteosarcoma cells by activating the STAT3 and RhoA-ROCK-LIMK2 pathways","volume":"10","author":"Zheng","year":"2020","journal-title":"Front Oncol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/8\/luae121\/58812155\/luae121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/8\/luae121\/58812155\/luae121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T01:41:46Z","timestamp":1723599706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae121\/7719047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,24]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae121","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,24]]},"article-number":"luae121"}}